Compare HLLY & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLLY | GLUE |
|---|---|---|
| Founded | 1903 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.6M | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | HLLY | GLUE |
|---|---|---|
| Price | $4.04 | $17.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $4.43 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.0M | 910.9K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $598,132,000.00 | $181,538,000.00 |
| Revenue This Year | $1.75 | $81.52 |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | ★ N/A | $70.71 |
| Revenue Growth | N/A | ★ 1112.27 |
| 52 Week Low | $1.60 | $3.50 |
| 52 Week High | $4.43 | $18.15 |
| Indicator | HLLY | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 75.58 |
| Support Level | $3.58 | $15.21 |
| Resistance Level | $3.90 | $17.63 |
| Average True Range (ATR) | 0.18 | 0.98 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 52.94 | 95.20 |
Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.